脘腹祛痛汤联合雷贝拉唑对慢性萎缩性胃炎患者血清G-17、CA724、PG水平的影响

摘要/Abstract

摘要： 目的研究脘腹祛痛汤联合雷贝拉唑对慢性萎缩性胃炎患者血清胃泌素-17（G-17）、糖类抗原724（CA724）和胃蛋白酶原（PG）水平的影响。方法选取2018年1月~2021年12月黄陵县人民医院收治的70例慢性萎缩性胃炎患者为研究对象,按照随机数表法分为对照组和观察组,每组35例。对照组服用雷贝拉唑,观察组在雷贝拉唑的基础上联用脘腹祛痛汤。比较两组的临床疗效,治疗前后的血清G-17、CA724和PG水平,治疗前后胃脘隐痛、泛吐清水、喜温喜按、四肢倦怠、饱胀和食少纳呆等中医证候评分。结果观察组患者的治疗有效率明显高于对照组（P<0.05）。治疗前,两组患者血清G-17、CA724和 PG水平比较差异无统计学意义（P>0.05）;治疗后,两组患者血清CA724、PGⅠ和G-17水平均升高（P<0.05）,PGⅡ水平降低（P<0.05）,且观察组血清CA724、PGⅠ和G-17水平高于对照组（P<0.05）,PGⅡ水平低于对照组（P<0.05）。治疗前,两组患者的胃脘隐痛、喜温喜按、饱胀、泛吐清水、四肢倦怠和食少纳呆证候评分比较差异无统计学意义（P<0.05）,治疗后,两组患者的上述证候评分均降低（P<0.05）,且观察组低于对照组（P<0.05）。结论脘腹祛痛汤联合雷贝拉唑治疗慢性萎缩性胃炎疗效显著,能有效调节血清G-17、CA724及PG水平,减轻胃黏膜损伤程度。¹

关键词: 脘腹祛痛汤, 雷贝拉唑, 慢性萎缩性胃炎, 胃泌素-17, 糖类抗原724, 胃蛋白酶原

Abstract: Objective To study the effect of Wanfu Qutong decoction combined with rabeprazole on the levels of serum gastrin-17 (G-17), carbohydrate antigen 724 (CA724) and pepsinogen (PG) in patients with chronic atrophic gastritis. Methods 70 cases of patients with chronic atrophic gastritis who were treated in Huangling County People's Hospital from January 2019 to December 2021were selected, and divided into two groups(the control group and observation group) according to the random number table method, with 35 cases in each group. The control group was treated with rabeprazole, and the observation group was treated with Wanfu Qutong Decoction on the basis of rabeprazole. The clinical efficacy in the two groups was compared. The levels of serum G-17, CA724 and PG in the two groups were detected, and the scores of TCM symptoms such as epigastric pain, tendency of warmness and pressing, fullness, generalized vomiting of clear water, four limbs burnout and anorexia were evaluated. Results The effective rate of the observation group was significantly higher than control group (P<0.05). Before treatment, there was no significant difference in the levels of serum G-17, CA724 and PG between the two groups (P>0.05). After treatment, the levels of serum CA724, PGⅠ and G-17 increased significantly (P<0.05), and the level of PGⅡ decreased significantly (P<0.05). The levels of serum CA724, PGⅠ and G-17 in the observation group were significantly higher than those in the control group (P<0.05), and the level of PGⅡ was significantly lower than that in the control group (P<0.05). Before treatment, there was no significant difference between the two groups in the scores of epigastric pain, tendency of warmness and pressing, fullness, generalized vomiting of clear water, four limbs burnout and anorexia (P>0.05). After treatment, the scores of the TCM symptoms above in the two groups decreased (P<0.05), and the observation group were significantly lower than those in the control group (P<0.05). Conclusion Wanfu Qutong decoction combined with rabeprazole has a significant effect on patients with chronic atrophic gastritis. It can effectively regulate the levels of serum G-17, CA724 and PG and reduce the degree of gastric mucosal injury.

Key words: Wanfu Qutong Decoction, rabeprazole, chronic atrophic gastritis, gastrin-17, carbohydrate antigen 724, pepsinogen

中图分类号:

R574.62

耿刘哲. 脘腹祛痛汤联合雷贝拉唑对慢性萎缩性胃炎患者血清G-17、CA724、PG水平的影响[J]. 中华养生保健, 2022, 40(21): 37-39.

GENG Liu-zhe. Effect of Wanfu Qutong decoction combined with rabeprazole on serum G-17, CA724 and PG levels in patients with chronic atrophic gastritis[J]. ZHONGHUA YANGSHENG BAOJIAN, 2022, 40(21): 37-39.

参考文献

[1] 洪珊珊,黄家惠,徐少军.荜铃胃痛颗粒联合四联疗法治疗幽门螺杆菌感染阳性慢性萎缩性胃炎的效果[J].中国医药导报,2021,18(29): 122-125.
[2] 喻勤,彭昌能,刘浒.复方丙谷胺西咪替丁对慢性萎缩性胃炎患者胃动力水平和胃黏膜PGE2水平的影响[J].实用药物与临床,2021, 24(2):138-142.
[3] Hossain M J, Islam M S, Shahriar S, et al.Comedication of rabeprazole sodium causes potential drug-drug interaction with diabetic drug linagliptin: in-vitro and in-silico approaches[J]. Journal of Experimental Biology and Agricultural Sciences, 2021, 9(4):528-542.
[4] 黎玉仙,陈秀芳,金明娣.疏肝和胃加减汤治疗慢性萎缩性胃炎疗效及对病理组织及血清炎性因子指标改善的研究[J].中华中医药学刊,2021,39(9):200-203.
[5] 中国中西医结合学会消化系统疾病专业委员会.慢性萎缩性胃炎中西医结合诊疗共识意见(2017年)[J].中国中西医结合消化杂志,2018,26(2):121-131.
[6] 张声生,唐旭东,黄穗平,等.慢性胃炎中医诊疗专家共识意见(2017)[J].中华中医药杂志,2017,32(7):3060-3064.
[7] 郑春娅,张瑞瑞,董文仙,等.慢性萎缩性胃炎抗Hp治疗后内镜特征与胃黏膜组织miR-1296-5p和miR-155-5p表达[J].中华医院感染学杂志,2021,31(10):1532-1536.
[8] 吴丹娜,陈朝聪,余华军,等.果胶铋联合磷酸铝凝胶对慢性萎缩性胃炎患者血清GAS ET IL-6 IL-12的影响[J].河北医学,2021,27(5):869-873.
[9] 战俊邑,张新,丁楠,等.基于数据挖掘方法分析曹志群治疗慢性萎缩性胃炎的用药规律[J].中药新药与临床药理,2021,32(5):733-738.
[10] 陈朝聪,蔡水苗,刘海珊.质子泵抑制剂联合抗生素治疗对Hp阳性慢性萎缩性胃炎患者血清胃泌素SIL-2R CRP水平及免疫功能的影响[J].河北医学,2020,26(3):429-432.
[11] 黄远程,朱朝阳,梁怀枫,等.基于数据挖掘的慢性非萎缩性胃炎与慢性萎缩性胃炎用药规律及差异研究[J].中国中医基础医学杂志,2021,27(3):457-461,471.
[12] 谢晓妹,冉静纯,赵唯含,等.基于”虚瘀毒”理论的中医药治疗慢性萎缩性胃炎的Meta分析[J].中华中医药学刊,2020,38(2):12-14.
[13] 赵蒙蒙,马红学,任顺平.任顺平教授运用升降理论之理气通降法辨治慢性萎缩性胃炎的经验撷要[J].中国医药导报,2021,18(29):142-145.
[14] 刘少伟,王彦刚,杨泽祺,等.王彦刚教授从”调升降,五散一养”论治慢性萎缩性胃炎[J].现代中西医结合杂志,2021,30(21):2372-2375.
[15] 徐珊珊,程红杰,高岩,等.脘腹祛痛汤结合埃索美拉唑镁肠溶片治疗慢性萎缩性胃炎临床研究[J].国际中医中药杂志,2021,43(10): 976-980.
[16] 黄妙灵,刘序友.慢性萎缩性胃炎病理改变与幽门螺旋杆菌感染及血清胃蛋白酶原,胃泌素-17的相关性[J].实用医学杂志,2020, 36(20):2838-2842.
[17] 秦维,王妹妹,王光栋.四磨汤联用西药对慢性萎缩性胃炎患者血清胃蛋白酶原,胃泌素-17及糖类抗原724水平影响[J].临床和实验医学杂志,2021,20(9):938-941.
[18] 郑惠之,赵荣,杨梅,等.龙胆泻肝汤联合三联疗法对Hp感染慢性胃炎患者血清PG及IL-8表达的影响[J].中国中西医结合消化杂志,2022,30(2):81-84,89.
[19] 邱坤武,朱联松,李桃.无痛胃镜下胃炎类型、炎症分级、OLGIM分期与Hp感染及血清PG水平的关系[J].湖南师范大学学报(医学版), 2021,18(4):272-275.